Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Gastrointestinal CancerHepatology

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC

doi: 10.1136/gutjnl-2025-334981

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Hepatology

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

J Gastroenterol Hepatol

Hsieh ML, Su TH, Lin YC, Chen YY, Tung CF, Huang LS, Wu CH, Peng YC, Hsieh VC

doi: 10.1111/jgh.70259

Hepatology

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Gastroenterology

Liu WY, Huang S, Ji H, Kim SU, Cheuk-Fung Yip T, Lai-Hung Wong G, Petta S, Tsochatzis E, Nakajima A, Bugianesi E, George Goh BB, Chan WK, Romero-Gomez M, Sanyal AJ, Boursier J, Hagström H, Calleja JL, de Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Lee HW, Pennisi G, Yoneda M, Armandi A, Kim-Jun Teh K, Gallego-Durán R, Asgharpour A, de Saint-Loup M, Shang Y, Llop E, Fournier C, Mahgoub S, Lara-Romero C, Canivet CM, Sau-Wai Chan M, Lin H, Chen LL, Targher G, Byrne CD, Du M, Wai-Sun Wong V, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1053/j.gastro.2025.02.034

Further Publications

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Am J Gastroenterol

Barritt AS 4th, Tapper EB, Newsome PN, Gazis D, Morris H, Mospan AR, Perez AD, Kim Y, Neuschwander-Tetri BA, Loomba R, Sanyal A, TARGET-NASH Investigators

doi: 10.14309/ajg.0000000000003595

Hepatology

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Lancet Gastroenterol Hepatol

Lazarus JV, Agirre-Garrido L, White TM, Arora AK, Manolas MI, Diaz LA, Arab JP, Zelber-Sagi S, Alkhouri N, Spearman CW, Schattenberg JM, Kondili LA, Carrieri P, Lofton HF, Jaisinghani P, Kumar S, Duseja A, El-Kassas M, Takahasi H, Shawcross DL, Stine JG, Villota-Rivas M, Miralles-Sanchez JE, Pannain S, Brennan PN, MASLD/MASH Collaborators

doi: 10.1016/S2468-1253(25)00300-0

Hepatology

Social Determinants of Health Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-analysis

Am J Gastroenterol

Abu-Rumaileh M, Dhoop S, Pace J, Qapaja T, Martinez ME, Tincopa M, Loomba R

doi: 10.14309/ajg.0000000000003421

Hepatology

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Hepatology

Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, Moylan CA, Rodriquez LM, Abdelmalek M, Villanueva A, Noureddin M, Yang JD

doi: 10.1097/HEP.0000000000001333

Related content

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Social Determinants of Health Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease Prevalence and Severity: A Systematic Review and Meta-analysis

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data